Jack Allen
Stock Analyst at Baird
(0)
# 4671
Out of 5,243 analysts
48
Total ratings
35.29%
Success rate
-19.01%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CARISMA Therapeutics | Downgrades: Neutral | 10 1 | 0.44 | 127.27% | 3 | Dec 12, 2024 | |
MiNK Therapeutics | Maintains: Outperform | 8 4 | 0.83 | 381.93% | 2 | Nov 15, 2024 | |
Vor Biopharma | Maintains: Outperform | 22 14 | 1.32 | 960.61% | 3 | Nov 8, 2024 | |
Arcellx | Maintains: Outperform | 77 106 | 64.59 | 64.11% | 5 | Nov 6, 2024 | |
Intellia Therapeutic... | Maintains: Neutral | 24 18 | 9.83 | 83.11% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 180 180 | 20.54 | 776.34% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 140 120 | 8.14 | 1374.2% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 8 | 3.1 | 158.06% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 46 52 | 39.67 | 31.08% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 84 | 28.39 | 195.88% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 200 25 | n/a | n/a | 3 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 8 | 1.63 | 390.8% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 21 6 | n/a | n/a | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 12 | 1.88 | 538.3% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 5 | 0.56 | 792.86% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 9 | n/a | n/a | 1 | Sep 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 28 | 1.35 | 1974.07% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 6 9 | 5.2 | 73.08% | 1 | Oct 7, 2021 |